NCT01648348

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: COMPLETED

Phase: PHASE1, PHASE2

Sponsor: National Cancer Institute (NCI)

Condition: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: stale_update_signal

Results signal: Low Signal

Operational burden: rare_population_signal | strict_eligibility_signal

Stopped reason

Context when available

No stop reason available in the current public record.